Altimmune has initiated Phase 3 testing of pemvidutide, a dual glucagon/GLP-1 receptor agonist, for metabolic dysfunction-associated steatohepatitis (MDASH). The compound represents a mechanistic approach to nonalcoholic fatty liver disease by simultaneously engaging two metabolic pathways implicated in hepatic fat accumulation and energy dysregulation.
Key Points
- Pemvidutide is a balanced 1:1 dual receptor agonist targeting glucagon and GLP-1
- Phase 3 PERFORMA trial evaluates safety and efficacy in MDASH patients
- Also investigates alcohol-associated liver disease and alcohol use disorder indications
Longevity Analysis
Fatty liver disease reflects upstream metabolic dysfunction—impaired energy production and hormonal signaling that cascade through multiple regulatory systems. A dual-mechanism approach addresses both glucagon-mediated fat mobilization and GLP-1–driven metabolic efficiency simultaneously, rather than single-pathway optimization. Success in Phase 3 would establish a precedent for treating the metabolic roots of hepatic pathology rather than managing symptoms downstream. The compound's investigation across metabolic dysfunction and alcohol-related liver injury suggests therapeutic potential in reversing organ damage tied to energy metabolism and stress response dysregulation.
Original published by LT Wire.